Know Labs to Exhibit at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
January 23 2024 - 9:00AM
Business Wire
The Company to present updated clinical
research results and developments of its non-invasive blood glucose
monitor
Know Labs, Inc. (NYSE American: KNW), an emerging developer of
non-invasive medical diagnostic technology, today announced the
company will be exhibiting at the International Fair of New
Technologies in Diabetes at the 17th International Conference on
Advanced Technologies & Treatments for Diabetes (ATTD) in
Florence, Italy on March 6-9, 2024.
The Company will share updates on the latest developments of its
non-invasive blood glucose monitor and present results from its
ongoing clinical research, with two abstracts accepted for e-poster
presentation in the scientific program. These results will be
presented by Dr. Virend K. Somers of the Mayo Clinic, who serves as
an author and co-investigator on Know Labs’ current clinical
research protocol. The protocol assesses the accuracy of the Know
Labs radiofrequency (RF) sensor for non-invasive blood glucose
measurement in participants with prediabetes and Type 2 diabetes
using venous blood as comparative reference.
During the conference Know Labs will sponsor an invitation-only
luncheon hosted by Children With Diabetes (CWD) where key thought
leaders in the diabetes management field will discuss non-invasive
glucose monitoring innovation.
For more information on Know Labs, visit www.knowlabs.co.
About Know Labs, Inc.
Know Labs, Inc. is a public company whose shares trade on the
NYSE American Exchange under the stock symbol “KNW.” The Company’s
platform technology uses spectroscopy to direct electromagnetic
energy through a substance or material to capture a unique
molecular signature. The technology can be integrated into a
variety of wearable, mobile or bench-top form factors. This
patented and patent-pending technology makes it possible to
effectively identify and monitor analytes that could only
previously be performed by invasive and/or expensive and
time-consuming lab-based tests. The first application of the
technology will be in a product marketed as a non-invasive glucose
monitor. The device will provide the user with accessible and
affordable real-time information on blood glucose levels. This
product will require U.S. Food and Drug Administration clearance
prior to its introduction to the market.
Safe Harbor Statement
This release contains statements that constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. These statements appear in a number of places in this
release and include all statements that are not statements of
historical fact regarding the intent, belief or current
expectations of Know Labs, Inc., its directors or its officers with
respect to, among other things: (i) financing plans; (ii) trends
affecting its financial condition or results of operations; (iii)
growth strategy and operating strategy; and (iv) performance of
products. You can identify these statements by the use of the words
“may,” “will,” “could,” “should,” “would,” “plans,” “expects,”
“anticipates,” “continue,” “estimate,” “project,” “intend,”
“likely,” “forecast,” “probable,” “potential,” and similar
expressions and variations thereof are intended to identify
forward-looking statements. Investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, many of which are beyond Know
Labs, Inc.’s ability to control, and actual results may differ
materially from those projected in the forward-looking statements
as a result of various factors. These risks and uncertainties also
include such additional risk factors as are discussed in the
Company’s filings with the U.S. Securities and Exchange Commission,
including its Annual Report on Form 10-K for the fiscal year ended
September 30, 2023, Forms 10-Q and 8-K, and in other filings we
make with the Securities and Exchange Commission from time to time.
These documents are available on the SEC Filings section of the
Investor Relations section of our website at www.knowlabs.co. The
Company cautions readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made.
The Company undertakes no obligation to update any forward-looking
statement to reflect events or circumstances after the date on
which such statement is made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240123862937/en/
For Know Labs Media Inquiries:
Matter Health Abby Mayo Knowlabs@matternow.com Ph. (617)
272-0592
Know Labs, Inc.: Jordyn Hujar jordyn@knowlabs.co Ph. (206)
629-6414
Know Labs (AMEX:KNW)
Historical Stock Chart
From Mar 2024 to Apr 2024
Know Labs (AMEX:KNW)
Historical Stock Chart
From Apr 2023 to Apr 2024